Annexin Pharmaceuticals AB Market Cap ($4.83 Million)
Market Cap & Net Worth: Annexin Pharmaceuticals AB (ANNX)
Annexin Pharmaceuticals AB market cap. Annexin Pharmaceuticals AB (ST:ANNX) has a market capitalization of $4.83 Million (Skr44.86 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #28591 globally and #630 in its home market, demonstrating a -17.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Annexin Pharmaceuticals AB's stock price Skr6.26 by its total outstanding shares 7165782 (7.17 Million). Also see Annexin Pharmaceuticals AB cash conversion from operations for how efficiently the company converts equity into cash flow.
Annexin Pharmaceuticals AB Market Cap History (2017–2026)
Annexin Pharmaceuticals AB market cap history from 2017 to 2026. Data shows change from $2.99 Million to $4.83 Million (-0.33% CAGR). Check Annexin Pharmaceuticals AB (ANNX) stock price for real-time trading data and today's change.
Index Memberships
Annexin Pharmaceuticals AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.29 Billion | 0.03% | #185 of 281 |
Weight: Annexin Pharmaceuticals AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Annexin Pharmaceuticals AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Annexin Pharmaceuticals AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Annexin Pharmaceuticals AB to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANNX by Market Capitalization
Companies near Annexin Pharmaceuticals AB in the global market cap rankings as of November 4, 2026. Also see ANNX total asset value for a full breakdown of the balance sheet.
Key companies related to Annexin Pharmaceuticals AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Annexin Pharmaceuticals AB (2017–2026)
Market capitalization of Annexin Pharmaceuticals AB from 2017 to today. Between 2017 and today, Annexin Pharmaceuticals AB's market cap moved from $2.99 Million to $ 4.83 Million, with a yearly change of -0.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr4.83 Million | -68.38% |
| 2025 | Skr15.27 Million | +4472.75% |
| 2024 | Skr333.91K | +66.54% |
| 2023 | Skr200.50K | -73.95% |
| 2022 | Skr769.61K | -0.20% |
| 2021 | Skr771.15K | -43.50% |
| 2020 | Skr1.36 Million | +51.76% |
| 2019 | Skr899.40K | +3.53% |
| 2018 | Skr868.70K | -70.94% |
| 2017 | Skr2.99 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Annexin Pharmaceuticals AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.83 Million USD |
| MoneyControl | $4.83 Million USD |
| MarketWatch | $4.83 Million USD |
| marketcap.company | $4.83 Million USD |
| Reuters | $4.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Annexin Pharmaceuticals AB
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmo… Read more